Mast cell activation syndrome (MCAS) happens when mast cells, a type of immune cell found throughout your body, release excessive amounts of inflammatory chemicals without an appropriate trigger. The causes range from genetic mutations that make mast cells inherently unstable to environmental exposures, infections, hormonal shifts, and autoimmune processes that push otherwise normal mast cells into overdrive. In many cases, several of these factors overlap, which is part of why MCAS can be so difficult to pin down.
What Mast Cells Actually Release
Understanding what goes wrong in MCAS starts with understanding what mast cells do when they activate. These cells sit in your connective tissues, skin, gut lining, and airways, acting as sentinels against infection and injury. When they detect a threat, they dump a cocktail of stored chemicals into surrounding tissue. Histamine is the most well-known: it causes blood vessels to widen, airways to constrict, smooth muscles to contract, and mucus production to increase. That’s why MCAS symptoms often look like an allergic reaction even when no allergen is involved.
But histamine is just one piece. Mast cells also release tryptase, a protein that can constrict blood vessels around the heart and contribute to inflammation in joints and organs. They produce prostaglandins, which recruit other immune cells to the area and activate nerve cells (contributing to pain). And they generate leukotrienes, which pull in even more immune cells and increase the permeability of blood vessel walls, allowing fluid to leak into tissues. In MCAS, this entire cascade fires too easily, too often, or without shutting off properly.
Genetic Causes: Clonal vs. Nonclonal MCAS
MCAS is divided into two broad categories based on genetics. In clonal MCAS, the mast cells themselves carry a mutation, most commonly a change called KIT D816V, in a gene that encodes a receptor on the mast cell surface. This receptor acts like an on/off switch for mast cell growth and activation. The mutation essentially jams the switch in the “on” position, making the cells more reactive and prone to inappropriate activation. Clonal MCAS shares this mutation with a related condition called mastocytosis, where mast cells accumulate in abnormally high numbers. In nonclonal MCAS, no such mutation is found, and the mast cells appear genetically normal but still behave abnormally.
A separate genetic trait called hereditary alpha-tryptasemia (HaT) has emerged as an important piece of the puzzle. People with HaT carry extra copies of a gene called TPSAB1, which leads to higher baseline levels of tryptase in the blood. This trait affects roughly 5.7 percent of the general population in the U.S., U.K., and E.U. It doesn’t cause MCAS on its own, but it appears to lower the threshold for mast cell reactions. HaT shows up in at least 8.5 percent of people who experience severe anaphylaxis from insect stings, suggesting it amplifies the body’s mast cell response to certain triggers.
Environmental and Chemical Triggers
For people with nonclonal MCAS, environmental exposures are among the most common activators. Mast cells react to foreign substances (sometimes called xenobiotics) by releasing their inflammatory mediators. A single acute exposure to certain chemicals, or repeated lower-level exposures over time, can sensitize mast cells so they become more reactive going forward.
The list of documented triggers is long: pesticides, solvents, volatile organic compounds from new construction or remodeling, tobacco smoke, engine exhaust, gasoline fumes, nail polish and remover, air fresheners, paint and thinner, fresh asphalt, cleaning supplies, and off-gassing from new carpet or furnishings. Historically, clusters of unexplained illness have been traced back to these kinds of exposures. EPA headquarters workers developed symptoms after new carpeting was installed. Gulf War veterans, casino workers exposed to pesticides, pilots and flight attendants exposed to cabin fume events, and firefighters who responded to the World Trade Center attacks all experienced patterns consistent with mast cell activation following chemical or environmental exposures. Mold exposure, both at home and in workplaces, is another frequently reported trigger.
Infections, Especially Long COVID
Viral and bacterial infections can activate mast cells as part of a normal immune response, but in some people, the activation doesn’t resolve after the infection clears. This has become particularly visible with long COVID. Research has shown that SARS-CoV-2 proteins, particularly the spike protein and nucleocapsid protein, can function essentially as allergens, prompting the body to produce IgE antibodies against them. IgE is the same class of antibody responsible for classic allergic reactions, and when it binds to mast cells, it primes them to degranulate.
What makes this especially problematic is that high concentrations of free IgE can activate mast cells even without an antigen present, amplifying immune responses in a self-sustaining loop. The virus also appears to trigger a shift toward IgG4 production as a compensatory response, which suggests the immune system is struggling to recalibrate after the initial allergic-like response. This mechanism helps explain why some people develop new-onset MCAS symptoms months after a COVID infection, with histamine-driven flushing, gut problems, and cardiovascular instability that persist long after the virus itself is gone.
The Connective Tissue Connection
One of the most striking patterns in MCAS is how frequently it appears alongside Ehlers-Danlos syndrome (EDS), a group of connective tissue disorders, and postural orthostatic tachycardia syndrome (POTS), a form of dysautonomia. This trio is common enough that clinicians sometimes call it “the trifecta.”
The connection isn’t coincidental. Mast cells live directly inside connective tissue, where they monitor for injury and infection. In EDS, the connective tissue matrix is structurally fragile, leading to constant mechanical stress, joint instability, and ongoing tissue remodeling. Emerging research suggests this chronic physical irritation keeps local mast cells in a heightened state of activation. Once triggered, these overreactive mast cells release histamine, tryptase, and other inflammatory chemicals that further degrade the already fragile connective tissue. This creates a feedback loop: weak connective tissue irritates mast cells, and the chemicals those mast cells release break down the connective tissue even more. The resulting inflammation can also affect blood vessel tone and autonomic nervous system function, which is where POTS enters the picture.
Autoimmune Mast Cell Activation
In some cases, the body’s own immune system directly activates mast cells through autoantibodies. The best-studied example involves antibodies that target the IgE receptor on mast cells, called FcεRIα. Normally, this receptor waits for IgE antibodies to dock on it before triggering degranulation. But autoantibodies can bind to the receptor directly and cross-link it, forcing the mast cell to release histamine without any allergen being present.
This mechanism has been most clearly demonstrated in chronic urticaria (persistent hives), where about 23 percent of patients have detectable autoantibodies against the IgE receptor and another subset produce autoantibodies against IgE itself. These autoantibodies are IgG-type, meaning the immune system is essentially using one class of antibody to hijack a receptor designed for a different class. The result is mast cell degranulation that looks and feels like an allergic reaction but has no external trigger. While most of this research has focused on skin mast cells, the same mechanism could contribute to systemic MCAS symptoms in other tissues.
Gut Dysbiosis and SIBO
The gastrointestinal tract contains one of the highest concentrations of mast cells in the body, and disruptions to the gut microbiome can trigger or worsen mast cell activation. Small intestinal bacterial overgrowth (SIBO), a condition where bacteria proliferate in a part of the gut where they don’t belong, is frequently linked to MCAS. The bacterial overgrowth drives local inflammation, and the resulting damage to the intestinal lining (sometimes called leaky gut) allows bacterial products to cross into the bloodstream, where they can activate mast cells systemically. For people already predisposed to MCAS through genetics or other factors, gut dysbiosis can be the tipping point that pushes symptoms from manageable to severe.
Hormonal Influences
Estrogen and progesterone both interact directly with mast cells, which helps explain why MCAS symptoms often worsen around menstruation, during perimenopause, or with hormonal contraceptive use. High estrogen spikes can trigger mast cells to release histamine and other mediators. Progesterone, on the other hand, has a calming effect on mast cells. During perimenopause, progesterone levels drop before estrogen does, removing that calming influence while estrogen continues to fluctuate unpredictably. The result is often a window of several years where MCAS symptoms intensify, with flares that track closely with the menstrual cycle or hormonal shifts.
This hormonal connection also helps explain why MCAS is diagnosed more frequently in women and why symptoms sometimes first appear or dramatically worsen during puberty, pregnancy, or the transition to menopause.
How MCAS Is Diagnosed
Because MCAS has so many potential causes, diagnosis follows a structured three-part criteria. First, you need episodic symptoms consistent with mast cell activation affecting at least two organ systems. These can include flushing, hives, itching, swelling, nausea, vomiting, diarrhea, abdominal cramps, wheezing, nasal congestion, rapid heart rate, drops in blood pressure, and headache. Second, blood tryptase levels need to rise by at least 20 percent above your personal baseline plus 2 ng/mL during or within four hours of a reaction. So if your baseline tryptase is 10 ng/mL, a reading of 14 or higher during a flare would meet the threshold. Third, your symptoms need to improve with medications that block or stabilize mast cell mediators.
All three criteria must be met, which is one reason MCAS remains underdiagnosed. The tryptase test requires blood to be drawn during or shortly after an episode, and many people don’t have access to a lab during their worst flares. Some clinicians also measure other mast cell mediators in urine, though the tryptase formula remains the most widely accepted standard.